Clinical Trial Update: Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update on acalabrutinib combined with venetoclax or obinutuzumab for treatment-naive chronic lymphocytic leukemia and small lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Gazyva (Obinutuzumab)
• Venclexta (venetoclax)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: RECRUITING